Solid polyglycol-based biocompatible pre-formulation
First Claim
Patent Images
1. A method of treating wounds of a mammal by delivering a solid polyglycol-based, fully synthetic, pre-formulation, comprising:
- (a) at least one solid first compound comprising more than two nucleophilic groups;
(b) at least one solid second compound comprising more than two electrophilic groups;
(c) optionally, a solid buffer component;
(d) optionally, a solid therapeutic agent; and
(e) optionally, a solid viscosity enhancerwherein the solid polyglycol-based, fully synthetic, pre-formulation polymerizes and/or gels at a target site of the wound to form a polyglycol-based, fully synthetic, biocompatible hydrogel polymer after addition of a liquid component, wherein the liquid component does not contain any first compound or second compound, and provided that the solid polyglycol-based, fully synthetic, pre-formulation does not contain any aqueous component.
6 Assignments
0 Petitions
Accused Products
Abstract
Provided herein are pre-formulations forming a biocompatible hydrogel polymer comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the biocompatible hydrogel polymer covers a wound in a mammal and adheres to the surrounding skin tissue. In other embodiments, the hydrogel polymer is delivered into a joint space to treat joint disease or navicular disease.
-
Citations
20 Claims
-
1. A method of treating wounds of a mammal by delivering a solid polyglycol-based, fully synthetic, pre-formulation, comprising:
-
(a) at least one solid first compound comprising more than two nucleophilic groups; (b) at least one solid second compound comprising more than two electrophilic groups; (c) optionally, a solid buffer component; (d) optionally, a solid therapeutic agent; and (e) optionally, a solid viscosity enhancer wherein the solid polyglycol-based, fully synthetic, pre-formulation polymerizes and/or gels at a target site of the wound to form a polyglycol-based, fully synthetic, biocompatible hydrogel polymer after addition of a liquid component, wherein the liquid component does not contain any first compound or second compound, and provided that the solid polyglycol-based, fully synthetic, pre-formulation does not contain any aqueous component. - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
-
8. A method of treating arthritis in a joint space in a mammal by delivering a solid polyglycol-based, fully synthetic, pre-formulation, comprising:
-
(a) at least one solid first compound comprising more than two nucleophilic groups; (b) at least one solid second compound comprising more than two electrophilic groups; (c) optionally, a solid buffer component; (d) optionally, a solid therapeutic agent; and (e) optionally, a solid viscosity enhancer wherein the solid polyglycol-based, fully synthetic, pre-formulation polymerizes and/or gels at a target site in the joint space to form a polyglycol-based, fully synthetic, biocompatible hydrogel polymer after addition of a liquid component, wherein the liquid component does not contain any first compound or second compound, and provided that the solid polyglycol-based, fully synthetic, pre-formulation does not contain any aqueous component. - View Dependent Claims (9, 10, 11, 12, 13, 14)
-
-
15. A method of treating navicular disease in a hoof of a horse by delivering a solid polyglycol-based, fully synthetic, pre-formulation, comprising:
-
(a) at least one solid first compound comprising more than two nucleophilic groups; (b) at least one solid second compound comprising more than two electrophilic groups; (c) optionally, a solid buffer component; (d) optionally, a solid therapeutic agent; and (e) optionally, a solid viscosity enhancer wherein the solid polyglycol-based, fully synthetic, pre-formulation polymerizes and/or gels at a target site in the hoof of the horse to form a polyglycol-based, fully synthetic, biocompatible hydrogel polymer after addition of a liquid component, wherein the liquid component does not contain any first compound or second compound, and provided that the solid polyglycol-based, fully synthetic, pre-formulation does not contain any aqueous component. - View Dependent Claims (16, 17, 18, 19, 20)
-
Specification